Liver and adipose tissue levels as well as serum levels of RBP4 are higher in obese subjects compared to lean subjects. In obese subjects tissue and serum levels of RPB4 are correlated with insulin sensitivity and hepatic triglyceride content.
ID
Bron
Verkorte titel
Aandoening
Obesity
Insulin resistance
Type 2 diabetes mellitus
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Circulating and tissue levels of RBP4, in relation to:<br>
1. Endogenous glucose production;<br>
2. Hepatic, peripheral and adipose tissue insulin sensitivity;<br>
3. Hepatic triglyceride content.
Achtergrond van het onderzoek
Retinol binding protein (RBP4) is a small 21 kDa protein that belongs to the family of lipocalins. RBP4 is primarily synthesized in hepatocytes, but other sites of synthesis are known including adipocytes. Recently RBP4 has been proposed as an adipokine that is involved in obesity-induced insulin resistance. We aim to assess whether serum and tissue RBP4 levels are elevated in these metabolically altered states and whether these levels are correlated with glucose fluxes. This gives more insight in the pathophysiological role of RBP4 in glucose intolerance and diabetes in obesity and will shed light on whether it would be useful to develop agents that decrease RBP4 expression.
Doel van het onderzoek
Liver and adipose tissue levels as well as serum levels of RBP4 are higher in obese subjects compared to lean subjects. In obese subjects tissue and serum levels of RPB4 are correlated with insulin sensitivity and hepatic triglyceride content.
Onderzoeksopzet
1. Screening;
2. Two weeks presurgery;
3. Surgery.
Onderzoeksproduct en/of interventie
N/A
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Female;
2. BMI > 35 kg/m2;
3. Age between 26 and 50 years;
4. Established T2DM.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Primary lipid disorder or secondary lipid disorder treated with fibrates;
2. T2DM treated with thiazolidinediones, DPP4-inhibitors or GLP1-analogues;
3. Any medical condition except for glucose intolerance, hypertension and secondary dyslipidemia;
4. Bleeding disorder;
5. Untreated primary hypothyroidism;
6. Contra-indications for MR scanning.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL3651 |
| NTR-old | NTR3835 |
| Ander register | METC AMC : 12/314 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |